Stockscreener 앱 받기
4.97
0.00%
0.00
시간 외 거래:
4.99
0.02
+0.40%
전일 마감가:
$4.97
열려 있는:
$4.74
하루 거래량:
1.24M
Relative Volume:
2.27
시가총액:
$48.66M
수익:
$21.73M
순이익/손실:
$-91.17M
주가수익비율:
-6.7162
EPS:
-0.74
순현금흐름:
$-286.43M
1주 성능:
-0.40%
1개월 성능:
+20.63%
6개월 성능:
-38.64%
1년 성능:
-72.25%
1일 변동 폭
$4.67
$5.03
1주일 범위
$4.40
$5.03
52주 변동 폭
$3.20
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
명칭
Bluebird Bio Inc
전화
339-499-9300
주소
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.97 | 48.86M | 21.73M | -91.17M | -286.43M | -0.74 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-11-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-11-15 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-08-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-12-11 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2023-12-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-19 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 개시 | JP Morgan | Overweight |
| 2023-03-07 | 개시 | Robert W. Baird | Outperform |
| 2022-08-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-07 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 재확인 | Barclays | Equal Weight |
| 2021-11-08 | 재확인 | Canaccord Genuity | Hold |
| 2021-11-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-11-08 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 재확인 | Wedbush | Neutral |
| 2021-11-08 | 재확인 | Wells Fargo | Equal Weight |
| 2021-08-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-08-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 재개 | William Blair | Mkt Perform |
| 2021-08-09 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-03-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-02-17 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-02-16 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-11-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-11-02 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 개시 | Mizuho | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-27 | 업그레이드 | Stifel | Hold → Buy |
| 2020-02-19 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 재개 | BofA/Merrill | Buy |
| 2020-02-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-10-01 | 개시 | Stifel | Hold |
| 2019-08-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | 업그레이드 | Maxim Group | Hold → Buy |
모두보기
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN
bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - Insider Monkey
Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus
Carlyle, SK Capital to close bluebird bio deal on June 2 - Seeking Alpha
Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com India
Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio - Investing.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus
Carlyle's $5 Per Share Bluebird Bio Takeover Set for June 2 Close After Successful Tender - Stock Titan
Bluebird Bio Beats Investor Suit Over FDA Cancer Warning - Law360
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads By Investing.com - Investing.com India
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads - Investing.com
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
bluebird bio Reminds Stockholders to Act Now to Tender Shares fo - GuruFocus
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - BioSpace
Bluebird Beats Investor Lawsuit Over FDA Black Box Warning (1) - Bloomberg Law News
High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60 - Defense World
Bluebird Beats Patent Case Over Blood Disease Therapies - Law360
Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Tower Research Capital LLC TRC Reduces Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - BioSpace
Carlyle, SK Capital Partners and bluebird bio Provide Updated Te - GuruFocus
Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions - marketscreener.com
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates - MSN
bluebird bio updates terms of Carlyle, SK Capital buyout By Investing.com - Investing.com Canada
Carlyle and SK Capital boost Bluebird Bio bid, offering flexible payout terms - Private Equity Insights
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World
Bluebird: Q1 Earnings Snapshot - New Haven Register
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Bluebird Bio (BLUE) Surges on Amended Deal with Carlyle and SK C - GuruFocus
bluebird bio, Inc. SEC 10-Q Report - TradingView
Bluebird, Private Equity Firms Look To Sweeten Buyout Deal - insights.citeline.com
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equitybluebird bio (NASDAQ:BLUE) - Benzinga
bluebird bio shares soar after amended buyout offer from Carlyle, SK Capital - Proactive financial news
Bluebird Bio Stock Skyrockets on Revamped Buyout Offer - RagingBull
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67% - Fierce Pharma
Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish - MSN
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - citybiz
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agree - GuruFocus
Bluebird bio soars on amended deal with Carlyle, SK Capital - MSN
Bluebird Bio Inc (BLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):